AMG-208

AMG-208 is an orally active c-Met/RON dual selective inhibitor with an IC50 of 9 nM for c-Met. AMG-208 is a CYP3A4 inhibitor with an IC50 of 32 μM. AMG-208 has anti-cancer activity[1][2][3].

Product Specifications

CAS Number

[1002304-34-8]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

C-Met/HGFR; Cytochrome P450

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/AMG-208.html

Purity

99.86

Solubility

DMSO : 3.33 mg/mL (ultrasonic)

Smiles

COC1=CC=C2C(OCC3=NN=C4N3N=C(C=C4)C5=CC=CC=C5)=CC=NC2=C1

Molecular Formula

C22H17N5O2

Molecular Weight

383.40

Precautions

H302, H315, H319, H335

References & Citations

[1]Albrecht BK, et al. Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase. J Med Chem. 2008, 51 (10), 2879-2882.|[2]Boezio AA, et al. Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors. Bioorg Med Chem Lett. 2009, 19 (22), 6307-6312.|[3]Liu X, et al. Developing c-MET pathway inhibitors for cancer therapy: progress and challenges. Trends Mol Med. 2010,16 (1), 37-45.